• Victoria G Hall, Javier T Solera, Ghadeer Al-Alahmadi, Tina Marinelli, Heloise Cardinal, Charles Poirier, Geneviève Huard, PrasadG V RameshGVRTransplant Infectious Diseases and Multi-Organ Transplant Program (Hall, Solera, Al-Alahmadi, Marinelli, Humar, Kumar), University Health Network, Toronto, Ont.; Sir Peter MacCallum Department of Oncology (Hall), University of Melbourne, Sacha A De Serres, Debra Isaac, Rahul Mainra, Caroline Lamarche, Ruth Sapir-Pichhadze, Susan Gilmour, Atul Humar, and Deepali Kumar.
• Transplant Infectious Diseases and Multi-Organ Transplant Program (Hall, Solera, Al-Alahmadi, Marinelli, Humar, Kumar), University Health Network, Toronto, Ont.; Sir Peter MacCallum Department of Oncology (Hall), University of Melbourne, Parkville, Australia; Department of Infectious Diseases and Microbiology (Marinelli), Royal Prince Alfred Hospital, Sydney, AU; Department of Medicine (Cardinal, Poirier, Huard), Centre hospitalier de l'Université de Montréal, Montréal, Que.; Kidney Transplant Program (Prasad), St. Michael's Hospital, University of Toronto, Toronto, Ont.; Transplantation Unit, Renal Division, Department of Medicine (De Serres), University Health Center of Quebec, Faculty of Medicine, Laval University, Québec, Que.; Division of Transplant Medicine (Isaac), University of Calgary, Calgary, Alta.; Saskatchewan Transplant Program, Transplantation Unit, Renal Division (Mainra), Department of Medicine, University Health Centre of Saskatchewan, Saskatoon, Sask.; Hôpital Maisonneuve-Rosemont Research Institute (Lamarche), Université de Montréal, Montréal, Que.; Centre for Outcomes Research and Evaluation (Sapir-Pichhadze), Research Institute of McGill University Health Centre; Division of Nephrology, Department of Medicine (Sapir-Pichhadze), McGill University; Department of Epidemiology, Biostatistics, Occupational Health (Sapir-Pichhadze), McGill University, Montréal, Que.; Stollery Children's Hospital (Gilmour), University of Alberta, Edmonton, Alta.
• CMAJ. 2022 Aug 29; 194 (33): E1155E1163E1155-E1163.

BackgroundSevere COVID-19 appears to disproportionately affect people who are immunocompromised, although Canadian data in this context are limited. We sought to determine factors associated with severe COVID-19 outcomes among recipients of organ transplants across Canada.MethodsWe performed a multicentre, prospective cohort study of all recipients of solid organ transplants from 9 transplant programs in Canada who received a diagnosis of COVID-19 from March 2020 to November 2021. Data were analyzed to determine risk factors for oxygen requirement and other metrics of disease severity. We compared outcomes by organ transplant type and examined changes in outcomes over time. We performed a multivariable analysis to determine variables associated with need for supplemental oxygen.ResultsA total of 509 patients with solid organ transplants had confirmed COVID-19 during the study period. Risk factors associated with needing (n = 190), compared with not needing (n = 319), supplemental oxygen included age (median 62.6 yr, interquartile range [IQR] 52.5-69.5 yr v. median 55.5 yr, IQR 47.5-66.5; p < 0.001) and number of comorbidities (median 3, IQR 2-3 v. median 2, IQR 1-3; p < 0.001), as well as parameters associated with immunosuppression. Recipients of lung transplants (n = 48) were more likely to have severe disease with a high mortality rate (n = 15, 31.3%) compared with recipients of other organ transplants, including kidney (n = 48, 14.8%), heart (n = 1, 4.4%), liver (n = 9, 11.4%) and kidney-pancreas (n = 3, 12.0%) transplants (p = 0.02). Protective factors against needing supplemental oxygen included having had a liver transplant and receiving azathioprine. Having had 2 doses of SARS-CoV-2 vaccine did not have an appreciable influence on oxygen requirement. Multivariable analysis showed that older age (odds ratio [OR] 1.04, 95% confidence interval [CI] 1.02-1.07) and number of comorbidities (OR 1.63, 95% CI 1.30-2.04), among other factors, were associated with the need for supplemental oxygen. Over time, disease severity did not decline significantly.InterpretationDespite therapeutic advances and vaccination of recipients of solid organ transplants, evidence of increased severity of COVID-19, in particular among those with lung transplants, supports ongoing public health measures to protect these at-risk people, and early use of COVID-19 therapies for recipients of solid organ transplants.© 2022 CMA Impact Inc. or its licensors.

10 keywords...

hide…